Intuitive Surgical cuts procedure growth outlook as da Vinci demand slows
Slower use of robotic surgery systems is pressuring Intuitive Surgical’s growth expectations after the company records its fourth straight quarter of decelerating procedure expansion. The updated forecast keeps investor focus on rising competition and tighter hospital spending as demand for da Vinci procedures weakens to a four-year low.
Highlights
- Intuitive Surgical reports third quarter da Vinci procedure volume rose 14% year-over-year, its slowest pace in four years.
- Full-year 2023 da Vinci procedure growth outlook cut to 14–15%, down from a prior upper range of 15.5%.
- Continued competition and restrained hospital spending fuel a fourth straight quarter of decelerating growth, raising sector scrutiny among investors.
Updated outlook after weaker third quarter growth
As reported by Bloomberg, Intuitive Surgical says procedures performed with its da Vinci surgical robots rise about 14% in the third quarter from a year earlier, marking the weakest growth rate in four years.The company now expects full-year da Vinci procedure growth of between 14% and 15%, compared with its previous outlook that allowed for growth of as much as 15.5%.
Competition and hospital budgets remain in focus
The narrower forecast keeps concerns alive that increasing competition is weighing on Intuitive Surgical’s momentum. Reduced hospital spending is also adding pressure as healthcare providers remain more cautious on capital and procedure-related demand.The third quarter slowdown extends a broader pattern, with growth decelerating for a fourth consecutive quarter. That trend is likely to keep the robotic surgery sector under scrutiny as investors assess whether procedure volumes can reaccelerate.
In our earlier article on Micron Technology’s fading rally momentum, we highlighted bearish technical signals after the stock slipped below a rising wedge on the weekly chart. We noted weakening RSI and MACD readings and outlined key support and resistance zones that could define the next move as investors weigh whether the year’s gains can hold up amid broader pressure on chipmakers.